317 related articles for article (PubMed ID: 30030697)
1. The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies.
Fruhwirth GO; Kneilling M; de Vries IJM; Weigelin B; Srinivas M; Aarntzen EHJG
Mol Imaging Biol; 2018 Oct; 20(5):696-704. PubMed ID: 30030697
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
3. Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.
Volpe A; Adusumilli PS; Schöder H; Ponomarev V
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137649
[TBL] [Abstract][Full Text] [Related]
4. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.
Wu M; Zhang Y; Zhang Y; Liu Y; Wu M; Ye Z
Radiol Imaging Cancer; 2019 Nov; 1(2):e190031. PubMed ID: 33778682
[TBL] [Abstract][Full Text] [Related]
5. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
Front Immunol; 2020; 11():601497. PubMed ID: 33408716
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
7. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
8. Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Melero I; Berman DM; Aznar MA; Korman AJ; Pérez Gracia JL; Haanen J
Nat Rev Cancer; 2015 Aug; 15(8):457-72. PubMed ID: 26205340
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging to enlighten cancer immunotherapies and underlying involved processes.
van der Veen EL; Bensch F; Glaudemans AWJM; Lub-de Hooge MN; de Vries EGE
Cancer Treat Rev; 2018 Nov; 70():232-244. PubMed ID: 30308466
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging of Immunotherapy Targets in Cancer.
Ehlerding EB; England CG; McNeel DG; Cai W
J Nucl Med; 2016 Oct; 57(10):1487-1492. PubMed ID: 27469363
[TBL] [Abstract][Full Text] [Related]
11. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
12. The Immunoimaging Toolbox.
Mayer AT; Gambhir SS
J Nucl Med; 2018 Aug; 59(8):1174-1182. PubMed ID: 29794226
[TBL] [Abstract][Full Text] [Related]
13. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
14. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.
Masucci GV; Cesano A; Eggermont A; Fox BA; Wang E; Marincola FM; Ciliberto G; Dobbin K; Puzanov I; Taube J; Wargo J; Butterfield LH; Villabona L; Thurin M; Postow MA; Sondel PM; Demaria S; Agarwala S; Ascierto PA
J Transl Med; 2017 Nov; 15(1):223. PubMed ID: 29100546
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
Du Y; Qi Y; Jin Z; Tian J
Cancer Lett; 2019 Dec; 466():13-22. PubMed ID: 31499119
[TBL] [Abstract][Full Text] [Related]
17. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Mandal R; Chan TA
Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
[TBL] [Abstract][Full Text] [Related]
18. Tracking cellular and immune therapies in cancer.
Kurtz DM; Gambhir SS
Adv Cancer Res; 2014; 124():257-96. PubMed ID: 25287692
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
Sun L; Chen L; Li H
Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic properties of chemotherapy.
Fournier C; Rivera Vargas T; Martin T; Melis A; Apetoh L
Curr Opin Pharmacol; 2017 Aug; 35():83-88. PubMed ID: 28551360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
